Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
Authors:
- 1 December 2020
- journal article
- letter
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 125 (6) , e473-e474
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuseBritish Journal of Anaesthesia, 2019
- APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomyJournal of Pain Research, 2019
- Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical StudiesAnesthesia & Analgesia, 2018
- Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid AnalgesicsCell, 2017
- A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplastyJournal of Pain Research, 2017
- Structure-based discovery of opioid analgesics with reduced side effectsNature, 2016
- A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with MorphineThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profileBritish Journal of Anaesthesia, 2009
- Morphine Side Effects in β-Arrestin 2 Knockout MiceThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2Science, 1999